# **FULL VALUE OF VACCINE ASSESSMENT**





# **FULL VALUE OF VACCINE ASSESSMENT**

# GROUP B STREPTOCOCCUS VACCINE



Group B streptococcus vaccine: full value of vaccine assessment

ISBN 978-92-4-003752-6 (electronic version) ISBN 978-92-4-003753-3 (print version)

### © World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Group B streptococcus vaccine: full value of vaccine assessment. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and gueries on rights and licensing, see https://www.who.int/about/policies/publishing/copyright.

**Third-party materials**. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers**. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# **CONTENTS**

Acknowledgements	vi
Summary	<u>vii</u>
1. HOW TO USE THIS VALUE OF VACCINES ASSESSMENT FOR GROUP B STREPTOCOCCUS VACC	INES
1.1 Definition and purpose of a full value of vaccine assessment	1
1.2 Relationship to preferred product characteristics	1
1.3 Target audiences for full value of vaccines assessments	2
2. THE GLOBAL PUBLIC HEALTH NEED FOR A GROUP B STREPTOCOCCUS VACCINE	:
2.1 Description of Group B streptococcus disease	3
2.2 Current methods of surveillance, diagnosis, prevention and treatment	5
2.3 Major gaps in knowledge or research evidence	
3. GROUP B STREPTOCOCCUS VACCINES, A STRATEGIC PRIORITY FOR WHO	
3.1 Preferred product characteristics	
4. METHODOLOGY	9
4.1 Research designed to address major data gaps	9
4.2 Stakeholder analysis and involvement	<u>_</u>
5. DEVELOPMENT OF THE VACCINE	10
5.1 Biology of a maternal vaccine against Group B streptococcus.	10
5.2 Technical platforms under consideration	10
5.3 GBS vaccine development pipeline	10
5.4 Preclinical development: key issues	10
5.5 Clinical development and regulatory pathway: key issues	11
5.6 Vaccine efficacy: key issues	12
5.7 Vaccine safety: key issues	12
5.8 Major gaps in knowledge or research evidence	12

6. ESTIMATION OF DISEASE BURDEN	13
6.1 Modelling approach	13
6.2 Data inputs	13
6.3 Outcomes	15
6.4 Disease burden estimates of Group B streptococcus	15
6.5 Group B streptococcus and antimicrobial usage	17
6.6 Major gaps in knowledge or research evidence	17
7. IMPACT OF THE VACCINE ON DISEASE BURDEN	18
7.1 Modelling approach	18
7.2 Data inputs	19
7.3 Modelled outcomes	19
7.4 Estimated vaccine impact on disease burden	19
7.5 Major gaps in knowledge or research evidence	20
8. ECONOMIC ANALYSIS OF THE VALUE OF A GROUP B STREPTOCOCCUS VACCINE	21
8.1 Modelling approach and outcomes	21
8.2 Data inputs	21
8.3 Normative assumptions	21
8.4 Vaccine cost-effectiveness	22
8.5 Threshold vaccine price	22
8.6 Major gaps in knowledge or research evidence	22
9. RETURN ON INVESTMENT AND FINANCIAL SUSTAINABILITY OF A VACCINE	24
9.1 Defining the market	24
9.2 Vaccine demand forecast	24
9.3 Methodology for financial analysis	24
9.4 Outcomes of financial analysis	26
9.5 Results of financial analysis	26
9.6 Major gaps in knowledge or research evidence	26

10. IMPLEMENTATION OF THE VACCINE IN LOW RESOURCE SETTINGS	27
10.1 Policy formulation	27
10.2 Service delivery	28
10.3 Acceptance and demand for vaccine	28
10.4 Monitoring and evaluation	28
10.5 Major gaps in knowledge or research evidence	29
11. PRINCIPAL FINDINGS AND CONCLUSION	30
11.1 Principal findings	30
11.2 Next steps	30
11.3 Conclusion	32
References	33

# List of tables

Table 1.	Main features of Group B streptococcus infection and disease	3
Table 2.	Preferred product characteristics for a Group B streptococcus vaccine	8
Table 3.	Outcomes considered in the Group B streptococcus burden estimation and assessment of vaccine impact	15
Table 4.	Numbers of mothers vaccinated and outcomes averted (with uncertainty ranges in parentheses) by a Group B streptococcus vaccine, globally and by Sustainable Development Goal region.	20
Table 5.	Least and most favourable normative assumptions	22
Table 6.	Estimated clinical development investments required for a Group B steptococcus vaccine from a manufacturer's perspective	25
Table 7.	Summary of monitoring and evaluation components and adaptations required to incorporate a GBS vaccine	29
Table 8.	Principal findings, the quantitative data behind these, interpretation and next steps for different stakeholders	31
	of figures  The continuum of vaccine development	1
Fig. 1:	The continuum of vaccine development	1
_	Case ascertainment of invasive GBS disease in pregnant and postpartum women, stillbirths and infants (0–89 days)	
Fig. 3:	GBS vaccine pipeline	11
Fig. 4:	Group B streptococcus Natural History Model and case definitions	14
Fig. 5:	Global cases and deaths due to GBS disease by region: neonatal iGBS cases and maternal disease	16
Fig. 6:	Global cases and deaths due to GBS disease by region: deaths due to neonatal iGBS and stillbirth	16
Fig. 7:	Decision tree model used to estimate the impact and cost-effectiveness of maternal GBS vaccination	18
Fig. 8:	Net monetary benefit of GBS vaccines by least and most favourable normative assumptions and Sustainable Development Goal region	23
Fig. 9:	Threshold vaccine price by region under least and most favourable assumptions (censored at US\$ 500*)	23
Fig. 10:	Forecast of vaccine demand 2029–2040, by country income group	25
Fig. 11:	Survey respondents view of barriers to inclusion in national immunization programmes	27
F: 40	We are for the terms of the second of the se	

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5\_23527

